Figures & data
Table 1 Stage-specific therapy of stable COPD. Potential use of combination therapy with inhaled corticosteroid and bronchodilator instead of bronchodilator monotherapy
Figure 1 Database analysis for COPD. Search date: 2007-7-24.
Figure 2 Database analysis for COPD and quality of life. Search date: 2007-7-24.
Figure 3 Database analysis for COPD and quality of life and publication dates. Search date: 2007-7-24.
Figure 4 Outcomes in the TORCH study. In the combination regimen, salmeterol was administered at a dose of 50 μg and fluticasone propionate at a dose of 500 μg twice daily. Salmeterol alone was administered at a dose of 50 μg twice daily, and fluticasone propionate alone was administered at a dose of 500 μg twice daily. The effect of each study medication on health status (assessed according to changes in patients’ total scores on the St. George’s Respiratory Questionnaire). Vertical bars represent standard errors. Reproduced with permission from CitationCalverley PM, Anderson JA, Celli B, et al. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356:775–89. Copyright © 2007 Massachusetts Medical Society. All rights reserved.
Figure 5 Concept of the use of combined inhaled corticosteroids and betamimetics. While betamimetics target the symptom of bronchoconstriction corticosteroids should be beneficial in targeting inflammation and mucus secretion and thus abolishing further symptoms such as mucus-induced cough and airflow limitation.
